SNDX NASDAQ
Syndax Pharmaceuticals, Inc.
1W: +3.3%
1M: -23.4%
3M: -28.8%
YTD: -35.7%
1Y: +1.2%
3Y: +18.9%
5Y: -25.0%
$13.69
+0.47 (+3.56%)
Pre-Market: $13.80 (+0.12, +0.84%)
Weekly Expected Move ±9.2%
$11
$12
$13
$15
$16
Credit Risk of going bust: higher than 66% of companies Debt: 32.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.61 (down 96%), Syndax Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $589.4M against a stock market value of $1.22B.
Distance to default 3.78 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $294.1M (short-term plus half of long-term), stock volatility 51.7%; Altman Z'' -3.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.61 (down 96%), Syndax Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $589.4M against a stock market value of $1.22B.
Distance to default 3.78 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $294.1M (short-term plus half of long-term), stock volatility 51.7%; Altman Z'' -3.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-09-27
Earliest Filing
2024-11-04
Latest Filing
partner: 2
licensee: 1
Counterparties (Filed by SNDX)
3 relationshipsCompanies named in SNDX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Royalty Pharma Development Funding, LLC | RPRX | partner | Syndax entered into a Purchase and Sale Agreement with Royalty Pharma Development Funding, LLC for Royalty Pharma to pur | 2024-11-04 | View |
| Incyte Corporation | INCY | partner | Entered into a collaboration and license agreement for worldwide development and commercialization of axatilimab, includ | 2021-09-27 | View |
| UCB Biopharma Sprl | — | licensee | Granted Syndax an exclusive worldwide license for axatilimab in July 2016. | 2021-09-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-07-14 | Other Events; Exhibits | View | |
| 2026-06-10 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-06-10 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-06-04 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-12-19 | Amendments to Articles of Incorporation or Bylaws | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-26 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-16 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-05-05 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-03 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-12-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-11-18 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-12 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR